PURPOSE: 123I-labelled mZIENT (2β-carbomethoxy-3β-(3′-((Z)-2-iodoethenyl)phenyl)nortropane) has been developed as a radioligand for the serotonin transporter. The aim of this preliminary study was to assess its whole-body biodistribution in humans and estimate dosimetry. METHODS: Three healthy controls and three patients receiving selective serotonin reuptake inhibitor (SSRI) therapy for depression were included (two men, four women, age range 41-56 years). Whole-body imaging, brain SPECT imaging and blood and urine sampling were performed. Whole-body images were analysed using regions of interest (ROIs), time-activity curves were derived using compartmental analysis and dosimetry estimated using OLINDA software. Brain ROI analysis was performed to obtain specific-to-nonspecific binding ratios in the midbrain, thalamus and striatum. RESULTS: Initial high uptake in the lungs decreased in later images. Lower uptake was seen in the brain, liver and intestines. Excretion was primarily through the urinary system. The effective dose was estimated to be of the order of 0.03 mSv/MBq. The organ receiving the highest absorbed dose was the lower large intestine wall. Uptake in the brain was consistent with the known SERT distribution with higher specific-to-nonspecific binding in the midbrain, thalamus and striatum in healthy controls compared with patients receiving SSRI therapy. CONCLUSION: ¹²³I-mZIENT may be a promising radioligand for imaging the serotonin transporters in humans with acceptable dosimetry.
PURPOSE: 123I-labelled mZIENT (2β-carbomethoxy-3β-(3′-((Z)-2-iodoethenyl)phenyl)nortropane) has been developed as a radioligand for the serotonin transporter. The aim of this preliminary study was to assess its whole-body biodistribution in humans and estimate dosimetry. METHODS: Three healthy controls and three patients receiving selective serotonin reuptake inhibitor (SSRI) therapy for depression were included (two men, four women, age range 41-56 years). Whole-body imaging, brain SPECT imaging and blood and urine sampling were performed. Whole-body images were analysed using regions of interest (ROIs), time-activity curves were derived using compartmental analysis and dosimetry estimated using OLINDA software. Brain ROI analysis was performed to obtain specific-to-nonspecific binding ratios in the midbrain, thalamus and striatum. RESULTS: Initial high uptake in the lungs decreased in later images. Lower uptake was seen in the brain, liver and intestines. Excretion was primarily through the urinary system. The effective dose was estimated to be of the order of 0.03 mSv/MBq. The organ receiving the highest absorbed dose was the lower large intestine wall. Uptake in the brain was consistent with the known SERT distribution with higher specific-to-nonspecific binding in the midbrain, thalamus and striatum in healthy controls compared with patients receiving SSRI therapy. CONCLUSION: ¹²³I-mZIENT may be a promising radioligand for imaging the serotonin transporters in humans with acceptable dosimetry.
Authors: Mark M Goodman; Ping Chen; Christophe Plisson; Laurent Martarello; James Galt; John R Votaw; Clinton D Kilts; Gene Malveaux; Vernon M Camp; Bing Shi; Timothy D Ely; Leonard Howell; Jon McConathy; Charles B Nemeroff Journal: J Med Chem Date: 2003-03-13 Impact factor: 7.446
Authors: T C Pearson; D L Guthrie; J Simpson; S Chinn; G Barosi; A Ferrant; S M Lewis; Y Najean Journal: Br J Haematol Date: 1995-04 Impact factor: 6.998
Authors: Jonathan Cavanagh; James Patterson; Sally Pimlott; Deborah Dewar; Jos Eersels; Mary Frances Dempsey; David Wyper Journal: Biol Psychiatry Date: 2005-09-28 Impact factor: 13.382
Authors: Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Michael J Owens; John R Votaw; Mark M Goodman Journal: J Med Chem Date: 2006-11-16 Impact factor: 7.446
Authors: J P Seibyl; E Wallace; E O Smith; M Stabin; R M Baldwin; S Zoghbi; Y Zea-Ponce; Y Gao; W Y Zhang; J L Neumeyer Journal: J Nucl Med Date: 1994-05 Impact factor: 10.057
Authors: Andrew B Newberg; Karl Plössl; P David Mozley; James B Stubbs; Nancy Wintering; Michelle Udeshi; Abass Alavi; Tomi Kauppinen; Hank F Kung Journal: J Nucl Med Date: 2004-05 Impact factor: 10.057